Lillian Siu, MD, FRPCPC
Dr. Siu is the principal investigator for many phase I, II and III trials supported by NCI, NCIC and the pharmaceutical industry. Her major research focus is in the area of new anticancer drug development, particularly with respect to head and neck and gastrointestinal malignancies. She also has research interests in the design of novel dose-escalation schemes for phase I clinical trials, and the development of relevant biological endpoints for newer classes of anti-tumor compounds, especially the cytostatic agents with specific molecular targets such as signal transduction inhibitors and anti-angiogenics.
Locally, Dr. Siu is a member of the Research Ethics Board at the University Health Network. Nationally, she is a member of the NCIC Quality Assurance and Data Monitoring Committees. Dr. Siu has a strong background in clinical trial methodology and has been a faculty member for the 1998 joint ASCO/AACR Methods in Clinical Cancer Research workshop in Vail, while serving on the workshop program committee in 1999. She is the recipient of numerous awards such as the Elsie Winifred Crann Award at the University of Toronto in 2001, Teaching Awards in the Medical Oncology Residency Program for the last 3 consecutive years, and many others.